FLAMINGO study (96-week data)

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naïve adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

Molina J-M, Clotet B, van Lunzen J, et al, on behalf of the FLAMINGO Study Team

Lancet HIV 2015; 2: e127–36.

Read the full publication

You will need to register to view the full publication.

Sign me up for an account

UK/DTGP/0037/16(2)a Date of Prep: June 2017